Atriva to Initiate P-II Clinical Study Evaluating ATR-002 for Treatment of Patients with COVID-19
Shots:
- Atriva will commence P-II study assessing ATR-002 vs PBO in hospitalized patients with moderate COVID-19- expected to be initiated in July’2020
- ATR-002’s MOA inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in its preclinical studies. The dual antiviral and immunomodulatory effect allows the therapy to prevent progression to critical-stage COVID-19 in hospitalized patients
- ATR-002 is a MEK inhibitor targeting the intracellular Raf/MEK/ERK signaling pathway and has the potential to modulate the pro-inflammatory cytokine response of the body- thus avoiding overshooting cytokine response. The company has filed respective patents with the European Patent Office
Click here to read full press release/ article | Ref: PRNewswire | Image: Atriva
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com